In summary, this study confirms that TMZ has activity in AML, and indicates that anti-leukemic responses correlate with MGMT expression, particularly in previously untreated patients. This correlation supports in vitro data indicating that MGMT is an important mediator of leukemia cell resistance to this agent. These findings require validation in a follow-up study, and such a study is currently in progress. If confirmed, this would establish TMZ as a reasonable front-line therapy option for older AML patients who are poor candidates for conventional induction chemotherapy, and whose blasts demonstrate very low or absent MGMT expression. Furthermore, MGMT-negative AML may potentially be a useful target for TMZ-containing combination regimens.
A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias Leukemia (2007) 21, 824-827. doi:10.1038/sj.leu.2404525; published online 1 February 2007 In search of new markers for primitive hematopoietic cells, we have discovered that a recently described novel family of six putative transmembrane receptors, called slitrk1-slitrk6, are expressed on leukemic and lymphoma cells as well as hematopoietic stem cells. Slitrks belong to the leucine-rich repeat superfamily. They are single-pass transmembrane proteins, with homology to the slit family in the N-terminal extracellular domain and to the trk neurotrophin receptors in the C-terminal intracellular domain; hence assigned with the name slitrk.
1 Slitrks are highly conserved through evolution, with the human slitrks being 89-97% homologous to murine slitrks. 2 Aruga and Mikoshiba 1 described the expression pattern of these genes in the developing brain and spinal cord, as well as their involvement in controlling neurite migration and axonal guidance. We described previously the differential expression of slitrk5 (referred to as KIAA0918) on CD34 þ leukemic cell lines. 3 These data led to the hypothesis that they were relevant for hematopoiesis and possibly leukemogenesis. Results from the present study revealed that of 13 leukemic cell lines all four acute lymphoblastic leukemia, five out of seven acute myeloid leukemia and all of two chronic myelogenous leukemia cell lines express one or more members of the slitrk family (Figure 1a) . Comparison of the two closely related cell lines KG1 and KG1a revealed a specific expression pattern for slitrk4: it is expressed only by the undifferentiated variant KG1a, but not by the parental KG1 cell line. Only two leukemic cell lines do not express any of the slitrks, namely the myeloid leukemic cell lines NB4 and HL60. Although no clear-cut expression pattern could be detected, there is a trend toward lymphoblastic leukemic cells expressing more slitrk1 and slitrk6, whereas myeloid leukemic cells express more slitrk4 and slitrk5. The lymphoma cell lines showed a distinct expression pattern; for example, two cell lines (Daudi and GA10) show no expression of any of the slitrks whereas three cell lines (BC1, BC3 and BCBL1) show expression of five out of six slitrks (Figure 1b) . Most notably, the latter cell lines are all primary effusion lymphomas (PEL), a distinct clinical entity of diffuse body cavity-located lymphomas with no single-tumor mass as well as a poorer prognosis in comparison to other lymphomas. 4, 5 To assess expression patterns of slitrks by primary cells, we studied the expression of slitrk genes on human mononuclear cells (MNC) isolated from peripheral blood, human umbilical vein endothelial cells (HUVEC), human fetal bone stroma (BS), human foreskin fibroblast (HFF) and human umbilical vein stroma cells (HUVSC), and human Miz-hES5 embryonic stem cells by reverse transcriptase-polymerase chain reaction (RT-PCR). All six members of the slitrk family were expressed by human embryonic stem cells (ESC) (Figure 1c ). To exclude the possibility of contamination by mouse embryonic fibroblast (MEF) feeder cells, we demonstrated that human slitrk members were not expressed by MEF using the same set of primers. Human fetal BS showed a pattern similar to that of ESC, as did HUVSC, with all six members of slitrks being expressed on these cells. However, adult HFF showed a different and more specific pattern, expressing only slitrk1 and slitrk6 ( Figure 1a ). This suggests that embryonic and fetal tissues maintain the expression of slitrks during development, in contrast to terminally differentiated cells.
Analysis of slitrk expression on vascular cells revealed a highly contrasting expression pattern to that of fibroblasts. RT-PCR analysis showed that HUVEC expressed only slitrk4 and slitrk5 (Figure 1c) . Activation of HUVEC with interleukin1 (IL1) or phorbol-myristate acetate (PMA) had no major effect on the expression pattern of slitrk1-slitrk6, except for a slight increase in the expression of slitrk5. Human MNC isolated from peripheral blood of healthy donors by density gradient separation (Ficoll) express only slitrk4 and slitrk5 (Figure 1c ). This pattern of expression of slitrk4 and slitrk5 is identical to that detected on HUVECs, but highly different from the studied leukemic cell lines. This difference in slitrk expression between leukemic and lymphoma cell lines and normal MNC is possibly because of reactivation of slitrks during malignant transformation. Since MNC showed expression of slitrk4 and slitrk5, we studied the expression of these two genes in different fractions of MNCs (total MNC, CD8 þ , CD4 þ CD14 þ and CD19 þ ), using quantitative PCR (qPCR; Taqman) on a panel of commercially available complementary DNA (cDNAs; Human Blood Fractions MTC Panel by Clontech, Mountain View, CA, USA). qPCR revealed that slitrk4 is primarily expressed in the CD14 þ compartment (monocytes), whereas slitrk5 was mainly expressed by T-cells (CD8 þ and CD4 þ ) (Figure 2a) .
The initial finding of slitrks being expressed on CD34 þ leukemic cells prompted us to invesitgate the expression of slitrks on hematopoietic stem and progenitor cells. Hematopoietic CD34 þ CD38À as well as CD34 þ stem and progenitor cells were sorted from human bone marrow (MoFlo HighPerformance Cell Sorter, Dako Cytomation, Glostrup, Denmark) and isolated from cord blood and mobilized peripheral blood of healthy donors, respectively (magnetic cell sorting; MACS Miltenyi Biotec Inc., Auburn, CA, USA). qPCR analysis revealed that highly purified population of human CD34 þ CD38À hematopoietic stem and progenitor cells isolated from bone marrow express slitrk4 and slitrk5, but not other members of the slitrk family. The CD34 þ CD38 þ fraction also expressed slitrk4 and slitrk5, whereas the cells of the CD34À fraction expressed both genes at a very low level (Figure 2b ). Human CD34 þ hematopoietic progenitor cells isolated from umbilical cord blood also expressed both slitrk4 and slitrk5, whereas the CD34À population expressed significantly lower levels of slitrk4 and slitrk5 (Figure 2b ). This pattern is reproduced in the CD34 þ and CD34À populations purified from mobilized peripheral blood of healthy donors treated with granulocyte-colony stimulating factor (G-CSF) (Figure 2b) .
As the CD34À fraction expresses slitrk4 and slitrk5 only at a low level, we investigated the expression of these genes following cytokine-driven in vitro differentiation of human CD34 þ cells. The CD34 þ population purified from cord blood was selectively differentiated into myeloid/granulocytic, erythroid and megakaryocytic lineages using G-CSF, erythropoietin (EPO) or thrombopoietin (TPO), respectively, over 12 days. The phenotype of the differentiated cells was confirmed by flow cytometry using three lineage-specific markers, namely CD11b for the myeloid, CD41a for the megakaryocytic and 
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CD235a for the erythroid lineage (Figure 2c) . Remarkably, although the undifferentiated cells showed robust expression of slitrk4 and slitrk5, the expression of these genes was drastically downregulated upon differentiation into the analyzed lineages. Only very low levels of slitrk4 and slitrk5 were detected on the mature CD11b þ myeloid, CD41a þ megakaryocytic or CD235a þ erythroid (Figure 2d ). These data indicate that slitrk4 and slitrk5 are predominantly expressed on immature human hematopoietic stem and progenitor cells.
Hematopoietic stem cells have been studied for their potential in reconstituting hematopoiesis 6 as well as for their promise as targets in the treatment of hematological malignancies. 7 Here, we show for the first time that undifferentiated multipotent cells, including human ESC and fetal BS, express all six members of the slitrk family, indicating the potential importance of slitrks for the identification of these primitive cells during developmental processes. However, the adult stem and progenitor cells, for example human bone marrow CD34 þ CD38À cells and cord Expression of slitrk4 and slitrk5 by human primary cells and hematopoietic stem/progenitor cells and the effect of lineage commitment. (a) cDNA from total mononuclear cells (MNC) and fractions thereof were analyzed by qPCR (Taqman) for expression of slitrk4 and slitrk5: slitrk4 is expressed mainly in the monocytic compartment (CD14 þ ), whereas slitrk5 is primarily expressed by T-cells (CD8 þ and CD4 þ ); relative expression is given in manifolds of expression of total MNC (average), error bars represent standard deviation (n ¼ 3, independent measurement). (b) Cells were isolated using cell sorting (bone marrow) or magnetic isolation (cord blood and mobilized blood), and qPCR was performed on cDNA from the respective cells. The relative expression of slitrk4 and slitrk5 in hematopoietic stem and progenitor cells isolated from adult bone marrow, cord blood or mobilized peripheral blood is higher in the immature CD34 þ than in the CD34À populations. Bone marrow: representative results shown; cord blood and mobilized blood: expression of slitrk4 or slitrk5 on CD34-cells is represented in percent of the CD34 þ population (average) and error bars represent standard deviation (n ¼ 3, independent experiments). blood derived as well as mobilized CD34 þ cells, express only slitrk4 and slitrk5. Our study suggests that slitrks could be involved in normal as well as malignant hematopoiesis, as indicated by the expression on leukemias, and possibly in embryonic development. Thus, slitrks may constitute a novel marker of hematopoietic stem and progenitor cells and embryonic stem cells. Even so, further studies need to be conducted to elucidate further the biological function of the slitrks.
